Tyra Biosciences, Inc. (TYRA)

NASDAQ: TYRA · Real-Time Price · USD

9.40

-0.37 (-3.79%)

Mar 31, 2025, 1:27 PM EDT - Market open

Tyra Biosciences Employees

Tyra Biosciences had 60 employees as of December 31, 2024. The number of employees increased by 11 or 22.45% compared to the previous year.

Employees

60

Change (1Y)

11

Growth (1Y)

22.45%

Revenue / Employee

n/a

Profits / Employee

-$1,764,918

Market Cap

499.05M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	60	11	22.45%
Dec 31, 2023	49	11	28.95%
Dec 31, 2022	38	13	52.00%
Dec 31, 2021	25	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

TYRA News

3 days ago - Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - PRNewsWire
6 weeks ago - Tyra Biosciences to Present at Upcoming Investor Conferences - PRNewsWire
2 months ago - Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium - PRNewsWire
2 months ago - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) - PRNewsWire
5 months ago - Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights - PRNewsWire
5 months ago - Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) - PRNewsWire
5 months ago - Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? - Benzinga
5 months ago - Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC) - PRNewsWire